Medicine Advances最新文献

{"title":"Novel nanomaterials as photo-activated cancer diagnostics and therapy","authors":"Deepika Yadav,&nbsp;Rishabha Malviya","doi":"10.1002/med4.36","DOIUrl":"https://doi.org/10.1002/med4.36","url":null,"abstract":"<p>The word “theranostics” describes an emerging trend in medicine in which the distinction between diagnosis and therapy blurs. Light or photo is used in theranostics to obtain high precision and personalised treatment. As only malignant tissues need to be spared, photo-triggered theranostics provide highly selective targeting using real-time imaging. Using nanotechnology to organise a dual-modality approach is an efficient way to circumvent pharmacokinetic limitations. Photodynamic therapy has been used successfully in the clinic for a while now, and this has paved the path for photo-triggered theranostics to be developed. The use of light-activated theranostic nanoforms has progressed from preclinical studies in animals and labs to clinical trials in humans. As both nanomaterials and their methods of manufacture advance, the theranostic approach becomes more nuanced and may be used in a wider range of real-time imaging and therapy modalities. The depth of anatomical access is also expanding because of developments in light delivery technologies. Combined, these innovations will hasten early cancer diagnosis and make tailored treatment more feasible. A non-invasive assessment approach also increases patient compliance and reduces risk. Researchers constantly make strides in their effort to create more versatile photo-sensitive nanoparticles. With any luck, photo-triggered theranostics may significantly reduce toxicity. In order to provide a better and safer clinical outcome in cancer therapy, this review aims to highlight the latest and greatest innovation research in the domain of nanotheranostics and its photo-triggering, and to sketch the possibilities for further progression and integration of nanoconstructs and photo-delivery, and trying to target approach in photo-triggered theranostics.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"190-209"},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50153806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical management algorithms for late complications after colorectal and anal cancer—Basic treatment of late complications","authors":"Birthe Thing Oggesen,&nbsp;Marie Louise Sjødin Hamberg,&nbsp;Jacob Rosenberg","doi":"10.1002/med4.32","DOIUrl":"https://doi.org/10.1002/med4.32","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The aim of this work was to develop a basic treatment guideline set for late complications after treatment for colorectal and anal cancer. Furthermore, a prerequisite was that the guideline was appropriate and safe to use for all health care staff regardless of their educational level. Lastly, the set should cover the most common late complications for patients treated for colorectal and anal cancer, including stool, urinary, sexual, and depressive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The treatment algorithms were developed by doctors in the Late Complication Clinic and afterward they were discussed to establish consensus with external experts in different fields such as surgery, gastroenterology, dietitian, gynecology, urology, sexology, general practice, anesthesiology, and psychiatry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We have developed a practical basic guideline set covering the most common late complications after colorectal and anal cancer treatment. The guideline set can be used by both nurses and doctors. The treatment algorithms are a combination of ordinary treatment principles and the best possible evidence in the field of late complications after colorectal and anal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We have developed a basic treatment guideline set for late complications after treatment for colorectal and anal cancers. There is generally little evidence in the field of late complications, and the evidence is mostly based on consensus. To establish higher-level evidence for late complication treatment after colorectal and anal cancer, it is important to monitor and adjust the treatment algorithms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"260-269"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.32","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50138399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of the use of Ofatumumab in the treatment of relapsing-remitting multiple sclerosis","authors":"Peter Olujimi Odutola,&nbsp;Peter Oluwatobi Olorunyomi,&nbsp;Olanrewaju Olamide Olatawura,&nbsp;Ifeoluwapo Olorunyomi,&nbsp;Olukayode Oluyinka Madojutimi,&nbsp;Uju Okeke,&nbsp;Ayomide O. Fatunsin,&nbsp;Victoria Eneh","doi":"10.1002/med4.33","DOIUrl":"https://doi.org/10.1002/med4.33","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ofatumumab is the first monoclonal antibody developed specifically for treating relapsed multiple sclerosis (RMS). This disease (Multiple Sclerosis) includes relapsing–remitting multiple sclerosis (RRMS), a chronic autoimmune illness that affects the central nervous system (CNS), including the brain and spinal cord. The purpose of this study is to determine whether Ofatumumab is efficacious and safe in the treatment of relapsing–remitting multiple sclerosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An analysis of studies comparing Ofatumumab with placebo in people with relapsing-remitting multiple sclerosis was done in accordance with PRISMA guidelines. We looked up information in MEDLINE, SciSearch, BIOSIS Previews, Derwent Drug File, Embase, and International Pharmaceutical Abstracts. In patients with relapsing–remitting multiple sclerosis, randomized double-blind and non-randomized trials contrasting Ofatumumab with placebo were found by two independent investigators. Utilizing Review Manager 5.4.1, data were examined. The main results were total gadolinium-enhancing (Gd+) T1 lesions, annualized relapse rate, and new or expanding total T2 lesions. Secondary outcomes concentrated on general adverse events and adverse events related to infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three studies were included involving 334 patients, and the meta-analysis indicated that Ofatumumab showed good efficacy and safety in patients with relapsing forms of multiple sclerosis. The annual rate of relapse was significantly reduced by Ofatumumab (OR 0.51; 95% CI 0.27, 0.98; <i>P</i> = 0.04). Ofatumumab reduced the number of gadolinium-enhancing (Gd+) T1 lesions per scan (Mean difference −0.59; 95% CI −0.63, −0.55; <i>P</i> &lt; 0.05). Ofatumumab treatment decreased new or enlarging total T2 lesions significantly (Mean difference −1.03; 95% CI −1.29, −0.76; <i>P</i> &lt; 0.05). Infection-related adverse effects were seen more frequently with Ofatumumab shown by the odd ratio 0.48; 95% CI 0.22, 1.04; <i>P</i> = 0.06. Infection is, thus, a major limitation to its use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The meta-analysis indicated that Ofatumumab is efficacious and safe for patients with relapsing forms of multiple sclerosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"278-287"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.33","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50132933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of potential key ferroptosis genes in the pathogenesis of ankylosing spondylitis by bioinformatics","authors":"Guoxian He,&nbsp;Zexin Chen,&nbsp;Jiaxiao Li,&nbsp;Lanhui Zhang,&nbsp;Suling Liu,&nbsp;Yang Cui","doi":"10.1002/med4.31","DOIUrl":"https://doi.org/10.1002/med4.31","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ankylosing spondylitis (AS) is a disabling chronic inflammatory disease. Mechanisms of ferroptosis in AS remain unclear. Using bioinformatics analysis, we aimed to identify key molecules involved in ferroptosis, provide potential therapeutic targets for AS, and further explore mechanisms of ferroptosis in AS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>GSE25101 was downloaded from the Gene Expression Omnibus and intersected with a ferroptosis gene dataset. The ferroptosis-relate differentially-expressed genes were further subjected to functional enrichment analysis, protein interaction network analysis, and gene-miRNA interaction network analysis, from which potential key ferroptosis genes in the pathogenesis of ankylosing spondylitis were screened.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 20 differentially expressed genes were screened, most of which are involved in phosphoinositide 3 kinase-Akt or mitogen-activated protein kinase (MAPK) signaling pathways or the endoplasmic reticulum stress response. The following target genes were identified through protein-protein interaction network analysis and screening of key modules constructed from genes associated with PI3K-Akt and MAPK signaling pathways: TP53, PTEN, TLR4, HSPB1, DDIT3, and XBP1. In addition, PI3K-Akt and MAPK signaling were associated with oxidative stress, which may play a role in AS pathological ossification related to ferroptosis. Only hsa-miR-205-5p was found to target at least two genes by gene-miRNA interaction network analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Future therapeutic drug development may intervene by modulating MAPK or PI3K-Akt signaling pathways rather than directly affecting the interleukin 17 pathway. hsa-miR-205-5p may be a potential novel biomarker for AS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"219-233"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50132934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thoracic dumbbell giant schwannoma in a young woman: A case report","authors":"Zheng Jun,&nbsp;Yu Bing,&nbsp;Li Qing Song","doi":"10.1002/med4.30","DOIUrl":"https://doi.org/10.1002/med4.30","url":null,"abstract":"<p>Schwannomas, which are benign, are one of the most common intraspinal tumors, accounting for 29% of primary spinal tumors. Schwannomas have several other names, including neurinoma, neurilemmoma, and neuroma. They originate from Schwann cells, which were first described by Theodor Schwann, a German physiologist, biologist, and histologist. Here, we present a patient with a giant, thoracic, dumbbell-shaped schwannoma. This benign tumor protruded into the subcutaneous fascial layer, compressing the pleura and the left side of the thoracic spinal cord. Additionally, some of the spinous processes and laminae of the thoracic vertebrae were missing. Most patients with this type of tumor are asymptomatic; however, up to 11.7% of patients have symptoms that depend on the size and location of the tumor. Magnetic resonance imaging can accurately determine the extent of the tumor and any intraspinal component and is thus helpful in selecting the optimal surgical procedure.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"288-292"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.30","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50155682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data mining analysis of professor Qiu Changlin's Chinese Medicinal therapy for Parkinson's disease","authors":"Shuang Wu,&nbsp;Han Wu,&nbsp;Xuhong Jiang,&nbsp;Hongchen Li,&nbsp;Jie Luo","doi":"10.1002/med4.28","DOIUrl":"https://doi.org/10.1002/med4.28","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Parkinson's disease (PD) is a prevalent, progressive neurodegenerative disease that has been widely treated using dopamine replacement therapy. However, this therapy does not prevent the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Clinical experience has shown that Chinese medicines (CMs) can alleviate the side effects of Western medicines for PD and improve the quality of life of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This paper describes the collection and analysis of Professor Qiu Changlin's decoctions for PD and proposes new ideas on the Law of CM Clinical Formula Administration and Syndrome Differentiation of PD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A database of Professor Qiu's prescriptions for PD patients of Zhejiang Provincial Hospital of Chinese Medicine over 5 years (January 2018 to May 2022) was established and analyzed using Microsoft Excel 2019 and SPSS Modeler 22.0.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Frequency analysis of 1162 prescriptions comprising 232 CMs revealed 17 high-frequency CMs, including Shu Di Huang (Rehmanniae Radix Praeparata) and Chao Bai Shao (Paeoniae Radix Alba), and correlations among the CMs. The property (nature) of these CMs is warm, and the flavors are mainly bitter, sweet, and sour. Most enter the liver meridian. Based on cluster analysis, we obtained a core effective prescription that mainly comprises Tian Ma, Gou Teng Yin and Zuo Gui Wan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The core effective prescription is expected to inspire new ideas for the administration of CM clinical formulas and syndrome differentiation in PD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"270-277"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.28","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50155673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US","authors":"Shinichi Matsumoto,&nbsp;Noriaki Yamamoto","doi":"10.1002/med4.29","DOIUrl":"https://doi.org/10.1002/med4.29","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Previously, we performed encapsulated porcine islet xenotransplantation for the treatment of unstable type 1 diabetic patients and demonstrated the clinical benefit and safety in New Zealand and Argentina. Conversely, the treatment of type 1 diabetes differs from country to country; therefore, understanding the acceptance of the new treatment by patients and medical doctors in each country is important. In this study, a survey study of the acceptance of the encapsulated porcine islet xenotransplantation by the type 1 diabetic patients and medical doctors in the US was conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The questionnaires consisted of the acceptance of the encapsulated porcine islet xenotransplantation without immunosuppression, and the reasons for selecting and not selecting. Moreover, we conducted a sub-analysis among patient groups regarding severe hypoglycemia and HbA1c levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The majority of patients and doctors (patients, 63.8%; doctors, 70.0%) had a positive opinion to accept this treatment. A significantly high number of doctors selected no immunosuppression for selecting this treatment (patients, 35.5%; doctors, 53.6%; <i>p</i> &lt; 0.001), and a significantly high number of patients selected not insulin free for not selecting this treatment (patients 20.4%, doctors 12.4%, <i>p</i> &lt; 0.05). The high HbA1c group had the highest ‘definitely’ accept rate, which was significantly higher than those of the other HbA1c groups (High HbA1c group, 50.0%; other HbA1c groups, 22.2%; <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, the majority of US patients and doctors had positive opinions to accept the encapsulated porcine islet xenotransplantation. Type 1 diabetic patients with high HbA1c levels had the highest ‘definitely’ acceptance rates.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"210-218"},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.29","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50124587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crosstalk between cancer cells and the nervous system","authors":"Meng Huang,&nbsp;Gu Gong,&nbsp;Yicheng Deng,&nbsp;Xinmiao Long,&nbsp;Wenyong Long,&nbsp;Qing Liu,&nbsp;Wei Zhao,&nbsp;Rufu Chen","doi":"10.1002/med4.27","DOIUrl":"https://doi.org/10.1002/med4.27","url":null,"abstract":"<p>Crosstalk between tumors and the nervous system has emerged as a significant hallmark of human cancer. In the central nervous system, neurons closely interact with tumor cells, promoting the proliferation of glioma and neuroblastoma. Additionally, the peripheral nervous system plays a crucial role in reshaping the tumor microenvironment, modulating angiogenesis, and regulating immune cell function, while also directly promoting tumorigenesis and metastasis. Current research has elucidated some of the specific neural signaling mechanisms involved in this crosstalk, including neurotransmitters, neuropeptides, and growth factors. In this review, we aim to summarize these mechanisms and highlight the latest discoveries in various solid tumors, such as glioma, pancreatic, prostate, and gastrointestinal cancers. By understanding the intricate crosstalk between cancer cells and the nervous system, we can develop more effective and targeted treatments for cancer patients.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 3","pages":"173-189"},"PeriodicalIF":0.0,"publicationDate":"2023-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50141962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"XRCC1, ABCB1, CYP3A5 and GSTP1 gene polymorphism associated with platinum-based drugs induced hematotoxicity in Chinese oesophageal cancer patients","authors":"Shuang Chen,&nbsp;Xiao Xiao,&nbsp;Jianliang Chen,&nbsp;Yun Chen,&nbsp;Zixian Wang,&nbsp;Guodong Qiu,&nbsp;Shuyao Zhang,&nbsp;Shilong Zhong","doi":"10.1002/med4.22","DOIUrl":"https://doi.org/10.1002/med4.22","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hematotoxicity, including severe myelosuppression, is a common adverse drug reaction (ADR) during platinum-based treatment for oesophageal cancer (EC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>The aim of this study was to identify single-nucleotide polymorphisms (SNPs) associated with platinum-induced hematotoxicity in patients with EC, as the relationship between SNPs and this ADR is incompletely demonstrated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 262 patients receiving platinum-based chemotherapy (cisplatin, nedaplatin, carboplatin and oxaliplatin) were enrolled in this study. Ten SNPs in eight genes were genotyped via multiplex polymerase chain reaction and sequenced to evaluate their relationship with severe myelosuppression and its subset of leukopenia and neutropenia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multivariate logistic analysis of cisplatin cohort in severe leukopenia group showed an odds ratio (OR) of GG + GA <i>versus</i> AA in <i>ABCB1</i> rs1045642 was 5.83 (95% confidence interval (CI) 1.63–20.83, <i>p</i> = 0.007, false discovery rate (FDR) = 0.028), while the OR of AA <i>versus</i> AG + GG in rs1128503 was 0.34 (95% CI 0.14–0.86, <i>p</i> = 0.022, FDR = 0.044). In nedaplatin cohort of neutropenia group, the OR of AA <i>versus</i> GG, AA + AG <i>versus</i> GG in <i>GSTP1</i> rs1695 was 10.34 (95% CI 1.71–62.40, <i>p</i> = 0.011, FDR = 0.040) and 7.48 (95% CI 1.37–40.81, <i>p</i> = 0.020, FDR = 0.040) respectively. <i>XRCC1</i> rs1799782 GG genotype in nedaplatin cohort of myelosuppression group and <i>CYP3A5</i> rs776746 CT genotype in nedaplatin cohort of severe leukopenia group and platinum cohorts of all groups appeared to be risk factors with the <i>p</i> values less than 0.05, but FDR values were all greater than 0.05.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study identified SNPs of <i>XRCC1</i>, <i>ABCB1</i>, <i>CYP3A5</i> and <i>GSTP1</i> related to hematotoxicity of platinum-based drugs, thereby providing a novel theoretical basis for the prediction and prevention of ADRs in platinum-based chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"133-145"},"PeriodicalIF":0.0,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.22","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50146993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood immune inflammatory indicators predict prognosis in patients with coronary artery disease","authors":"Ju-E Liu,&nbsp;Shufen Zheng,&nbsp;Kai Chen,&nbsp;Jing Wang,&nbsp;Xiaoqi Liu,&nbsp;Weihua Lai,&nbsp;Qian Zhu,&nbsp;Zhuoyi Wu,&nbsp;Jinxiu Meng,&nbsp;Shuang Xia,&nbsp;Yong Liu,&nbsp;Shilong Zhong","doi":"10.1002/med4.24","DOIUrl":"https://doi.org/10.1002/med4.24","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The relationship between the combined hematological parameters and echocardiography and long-term prognosis in patients with coronary artery disease (CAD) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined the ability of hematological parameters to predict all-cause death and major adverse cardiovascular events (MACE) based on Lasso Cox regression analysis. The significant predictors of hematological parameters from the Lasso Cox model were analyzed via multivariate Cox regression analysis and by adjusting for echocardiographic data. We calculated the continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI) of the hematological parameters to assess the improvement in prediction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A low hemoglobin and lymphocyte ratio and high hematocrit, red blood cell distribution width-coefficient of variation, and monocyte ratio significantly increased the risk of MACE and death in CAD patients. Neutrophil-to-lymphocyte ratio was associated with MACE but not death in CAD patients. After adjustment for echocardiographic parameters, hemoglobin, hematocrit, and lymphocyte ratio remained independently related to death and MACE. The addition of hematological and echocardiographic parameters to the Framingham risk score model significantly improved the area under the curve of mortality (0.794 <i>vs</i>. 0.713, <i>p</i> = 0.0007) and reclassification with cNRI of 30.6% (<i>p</i> = 0.002) and IDI of 0.055 (<i>p</i> &lt; 0.001). Mendelian randomization analyses identified that fibrinogen and neutrophil-to-lymphocyte ratio were associated with increased brain natriuretic peptide and decreased left ventricular ejection fraction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that the blood immune inflammatory indicators fibrinogen and neutrophil-to-lymphocyte ratio were causally associated with the risk of heart failure after CAD. The combination of hematological biomarkers and echocardiography parameters as predictor variables is a useful predictive tool for all-cause mortality in patients with CAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"146-157"},"PeriodicalIF":0.0,"publicationDate":"2023-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.24","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}